Jan. 2022
冲中記念成人病研究所 研究助成

Oct. 2021
第1回 日本糖尿病学会 キャリアデベロップメント報奨金

Dec. 2019
臨床医学振興財団研究助成

Feb. 2015
上原記念生命科学財団研究助成金

Nov. 2014
第3 回万有医学奨励賞

Oct. 2014
日本糖尿病合併症学会Young Investigator Award
International academic award

Oct. 2012
慈恵医師会研究奨励賞

Sep. 2012
万有生命科学振興国際交流財団研究助成

Aug. 2011
武田科学振興財団研究助成金

Jul. 2007
American Heart Association Postdoctoral Fellowship

Feb. 2007
かなえ医薬振興財団海外留学助成金

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes
Takaya Matsushita; Yukihiro Wada; Masuo Saburi; Kazuo Kobayashi; Shunichiro Tsukamoto; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hiromichi Wakui; Keizo Kanasaki; Yoshimi Muta; Kouichi Tamura; Yasuo Takeuchi; Masao Toyoda
Hypertension Research, 04 Jun. 2026

Serum triglyceride levels and incidence of diabetes in a general Japanese population: ISSA-CKD study
Tomohiro Fukushima; Takako Fujii; Shintaro Ishida; Makiko Abe; Miki Kawazoe; Toshiki Maeda; Chikara Yoshimura; Shunsuke Funakoshi; Daisuke Morita; Yori Inoue; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima
Diabetes Epidemiology and Management, Jun. 2026, 21:100320 - 100320

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE.
Satoshi Miyamoto; Hiddo J L Heerspink; Dick de Zeeuw; Kota Sakamoto; Michihiro Yoshida; Masao Toyoda; Daisuke Suzuki; Takashi Hatanaka; Tohru Nakamura; Shinji Kamei; Satoshi Murao; Kazuyuki Hida; Shinichiro Ando; Hiroaki Akai; Yasushi Takahashi; Munehiro Kitada; Hisashi Sugano; Tomokazu Nunoue; Akihiko Nakamura; Motofumi Sasaki; Tatsuaki Nakatou; Kei Fujimoto; Daiji Kawanami; Takashi Wada; Nobuyuki Miyatake; Hiromi Kuramoto; Kenichi Shikata
Kidney international reports, May 2026, 11(5):106374 - 106374

Alcohol consumption and the incidence of hyperuricemia in Japanese men and women.
Tamami Ueno; Kazumi Kawano; Chihiro Nohara; Kaori Maki; Kazuyo Iwanaga; Akiko Morinaga; Shunsuke Funakoshi; Makiko Abe; Atsushi Satoh; Miki Kawazoe; Toshiki Maeda; Chikara Yoshimura; Koji Takahashi; Kazuhiro Tada; Kenji Ito; Tetsuhiko Yasuno; Shigeaki Mukobara; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima
Scientific reports, 16 Apr. 2026

Association between serum phosphate levels within the normal range and all-cause mortality among US adults.
Mayuko Yamamoto; Sho Katsuragawa; Yuichi Takashi; Dai Nagata; Kyoko Toyokawa; Kosuke Inoue; Daiji Kawanami
Journal of the Endocrine Society, Mar. 2026, 10(3):bvag021

Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.
Shigehiro Katayama; Stefan D Anker; Dalong Zhu; SungGyun Kim; Ming-Ju Wu; Daiji Kawanami; Peter Rossing; Luis Miguel Ruilope; Christiane Ahlers; Meike Brinker; Amaninder Mann; Yunjing Tian; Satoshi Yamashita; Bertram Pitt
Journal of diabetes and its complications, Jan. 2026, 40(1):109213 - 109213

Fingertip skin autofluorescence as a non-invasive marker for vascular complications in patients with type 2 diabetes.
Minoru Takeshita; Takeshi Matsumura; Aiko Arimura; Hiroyuki Takahashi; Yoshimi Muta; Shigeru Kawade; Dai Yamagami; Takahisa Deguchi; Tatsuya Kondo; Mikihiro Yamanaka; Ryoji Nagai; Daiji Kawanami; Toshihiko Yanase; Takashi Nomiyama; Yoshihiko Nishio; Eiichi Araki; Naoto Kubota
Journal of diabetes investigation, Dec. 2025, 16(12):2201 - 2212

Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study.
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Mari Sotozawa; Kyoji Chiba; Yuki Senda; Saki Hideshima; Yuichi Takashi; Hisashi Yokomizo; Takuya Hashimoto; Kei Takeshita; Shunichiro Tsukamoto; Miwako Yomota; Miwa Ota; Atsuhito Tone; Moritsugu Kimura; Takaya Matsushita; Daisuke Suzuki; Takashi Murata; Daisuke Tsuriya; Kouichi Tamura; Keizo Kanasaki; Daiji Kawanami
JMA journal, 15 Oct. 2025, 8(4):1269 - 1275

A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
Daisuke Yabe; Yoshiyuki Hamamoto; Daiji Kawanami; Rimei Nishimura; Yasuo Terauchi; Hanan Amadid; Uffe Christian Braae; Atheline Major-Pedersen; Ryo Suzuki
Journal of diabetes investigation, Oct. 2025, 16(10):1794 - 1807

Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE).
Tetsuya Babazono; Takeshi Osonoi; Hideki Okamoto; Yukiko Onishi; Shinya Nakamoto; Masayuki Kashima; Daiji Kawanami; Eitaro Nakashima; Kei Watabe; Noriko Nunami; Katsuhiko Hagi
Journal of diabetes investigation, Oct. 2025, 16(10):1808 - 1819

Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection during Burosumab Therapy.
Dai Nagata; Yuichi Takashi; Mayuko Yamamoto; Kyoko Toyokawa; Kensuke Makihata; Haruki Koganemaru; Saki Hideshima; Yoshimi Muta; Hisashi Yokomizo; Hironori Fukumoto; Shizuhide Nakayama; Hiroko Muta; Mikiko Aoki; Hiroshi Abe; Takuaki Yamamoto; Makoto Hamasaki; Daiji Kawanami
Internal medicine (Tokyo, Japan), 01 Sep. 2025, 64(17):2597 - 2603

Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study).
Daisuke Tsuriya; Kazuo Kobayashi; Kei Takeshita; Takuya Hashimoto; Moritsugu Kimura; Yoshimi Muta; Hisashi Yokomizo; Yuichi Takashi; Shunichiro Tsukamoto; Kouichi Tamura; Keizo Kanasaki; Daiji Kawanami; Masao Toyoda
Journal of diabetes investigation, Jul. 2025, 16(7):1243 - 1253

Association between self-stigma and diabetic complications in Japanese people with type 2 diabetes: a cross-sectional study.
Mayuko Yamamoto; Yuichi Takashi; Masashi Ishizu; Kyoko Toyokawa; Dai Nagata; Kensuke Makihata; Haruki Koganemaru; Tomoki Sakamoto; Kayoko Teshima; Yuka Urata; Yoshimi Muta; Hisashi Yokomizo; Dan Sekiguchi; Yasutaka Maeda; Masae Minami; Asuka Kato; Daiji Kawanami
BMJ open, 17 Jun. 2025, 15(6):e095698

Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Shunichiro Tsukamoto; Daisuke Tsuriya; Yuichi Takashi; Hisashi Yokomizo; Kei Takeshita; Takuya Hashimoto; Moritsugu Kimura; Kouichi Tamura; Keizo Kanasaki; Daiji Kawanami
The Tokai journal of experimental and clinical medicine, 20 Apr. 2025, 50(1):1 - 9

Relationship of dietary intake and eating behaviors with glycemic control and body weight under long-term treatment with dapagliflozin: an exploratory prospective study.
Hisashi Yokomizo; Daiji Kawanami; Noriyuki Sonoda; Yasuhiro Ono; Yasutaka Maeda; Jun Itoh; Takeshi Tohyama; Masayuki Hirose; Hiroko Watanabe; Junji Kishimoto; Yoshihiro Ogawa; Toyoshi Inoguchi
Diabetology international, Apr. 2025, 16(2):303 - 315

Rho-associated, coiled-coil-containing protein kinase 2 regulates expression of mineralocorticoid receptor to mediate sodium reabsorption in mice.
Kensuke Sekiguchi; Keiichiro Matoba; Yosuke Nagai; Satoru Nagao; Shinji Ohashi; Etsuko Mitsuyoshi; Takeshi Hayashi; Daiji Kawanami; Tamotsu Yokota; Hirotaka Shibata; Kazunori Utsunomiya; Rimei Nishimura
Biochemical and biophysical research communications, 03 Dec. 2024, 736:150874 - 150874

PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
Daisuke Yabe; Yoshiyuki Hamamoto; Daiji Kawanami; Rimei Nishimura; Yasuo Terauchi; Hanan Amadid; Uffe Christian Braae; Atheline Major-Pedersen; Ryo Suzuki
Journal of diabetes investigation, Nov. 2024, 15(11):1566 - 1577

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Satoshi Miyamoto; Hiddo J L Heerspink; Dick de Zeeuw; Kota Sakamoto; Michihiro Yoshida; Masao Toyoda; Daisuke Suzuki; Takashi Hatanaka; Tohru Nakamura; Shinji Kamei; Satoshi Murao; Kazuyuki Hida; Shinichiro Ando; Hiroaki Akai; Yasushi Takahashi; Munehiro Kitada; Hisashi Sugano; Tomokazu Nunoue; Akihiko Nakamura; Motofumi Sasaki; Tatsuaki Nakatou; Kei Fujimoto; Daiji Kawanami; Takashi Wada; Nobuyuki Miyatake; Hiromi Kuramoto; Kenichi Shikata
Kidney international, Nov. 2024, 106(5):972 - 984

Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
Yuichi Takashi; Daiji Kawanami; Seiji Fukumoto
Current opinion in endocrinology, diabetes, and obesity, 01 Aug. 2024, 31(4):170 - 175

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
Shunichiro Tsukamoto; Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiromichi Wakui; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yoshimi Muta; Yuichi Takashi; Kouichi Tamura
Diabetes, obesity & metabolism, Aug. 2024, 26(8):3248 - 3260

Deletion of podocyte Rho-associated, coiled-coil-containing protein kinase 2 protects mice from focal segmental glomerulosclerosis.
Keiichiro Matoba; Yosuke Nagai; Kensuke Sekiguchi; Shinji Ohashi; Etsuko Mitsuyoshi; Masayuki Shimoda; Toshiaki Tachibana; Daiji Kawanami; Tamotsu Yokota; Kazunori Utsunomiya; Rimei Nishimura
Communications biology, 02 Apr. 2024, 7(1):402 - 402

Relationship between abdominal circumference and the incidence of hyperuricemia in the general Japanese population.
Kazumi Kawano; Tamami Ueno; Toshiki Maeda; Chihiro Nohara; Kaori Maki; Kazuyo Iwanaga; Akiko Morinaga; Shunsuke Funakoshi; Makiko Abe; Atsushi Satoh; Miki Kawazoe; Chikara Yoshimura; Koji Takahashi; Kazuhiro Tada; Kenji Ito; Tetsuhiko Yasuno; Shigeaki Mukobara; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima
Scientific reports, 25 Feb. 2024, 14(1):4573 - 4573

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Kouichi Tamura; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yuichi Takashi; Daiji Kawanami
Frontiers in pharmacology, 2024, 15:1358573 - 1358573

Association between serum ALT levels and incidence of new-onset diabetes in general population of Japanese: a longitudinal observational study (ISSA-CKD).
Akiko Morinaga; Kazuyo Iwanaga; Kaori Maki; Tamami Ueno; Kazumi Kawano; Shunsuke Funakoshi; Toshitaka Yamanokuchi; Masayoshi Tsuji; Makiko Abe; Atsushi Satoh; Miki Kawazoe; Toshiki Maeda; Chikara Yoshimura; Koji Takahashi; Kazuhiro Tada; Kenji Ito; Tetsuhiko Yasuno; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima
BMJ open, 07 Aug. 2023, 13(8):e074007

Elevation in white blood cell count and development of hyper LDL cholesterolemia.
Shota Okutsu; Yoshifumi Kato; Hiroaki Takeoka; Shunsuke Funakoshi; Toshiki Maeda; Chikara Yoshimura; Miki Kawazoe; Atsushi Satoh; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Hideyuki Fujii; Shigeaki Mukoubara; Keijiro Saku; Shohta Kodama; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima; Shigeki Nabeshima
Scientific reports, 22 May 2023, 13(1):8292 - 8292

Serum triglyceride levels and incidence of hypertension in a general Japanese population: ISSA-CKD study.
Shintaro Ishida; Seiji Kondo; Shunsuke Funakoshi; Makiko Abe; Atsushi Satoh; Miki Kawazoe; Toshiki Maeda; Chikara Yoshimura; Yoshihiro Nishida; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Daiji Kawanami; Shin-Ichiro Miura; Shohta Kodama; Keijiro Saku; Shigeaki Mukobara; Kosuke Masutani; Hisatomi Arima
Hypertension research : official journal of the Japanese Society of Hypertension, May 2023, 46(5):1122 - 1131

Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease.
Yosuke Nagai; Keiichiro Matoba; Hideji Yako; Shinji Ohashi; Kensuke Sekiguchi; Etsuko Mitsuyoshi; Kazunori Sango; Daiji Kawanami; Kazunori Utsunomiya; Rimei Nishimura
Biochemical and biophysical research communications, 15 Mar. 2023, 649:32 - 38

Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yoshimi Muta; Yuichi Takashi; Kouichi Tamura
Diabetes & vascular disease research, 2023, 20(6):14791641231222837 - 14791641231222837

A simple questionnaire for the detection of testosterone deficiency in men with late-onset hypogonadism.
Yuko Akehi; Makito Tanabe; Hiromi Yano; Yuichi Takashi; Daiji Kawanami; Takashi Nomiyama; Toshihiko Yanase
Endocrine journal, 28 Nov. 2022, 69(11):1303 - 1312

Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism.
Yosuke Nagai; Keiichiro Matoba; Yusuke Takeda; Hideji Yako; Tomoyo Akamine; Kensuke Sekiguchi; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Sango; Daiji Kawanami; Kazunori Utsunomiya; Rimei Nishimura
Kidney international, Sep. 2022, 102(3):536 - 545

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Satoshi Miyamoto; Hiddo J L Heerspink; Dick de Zeeuw; Masao Toyoda; Daisuke Suzuki; Takashi Hatanaka; Tohru Nakamura; Shinji Kamei; Satoshi Murao; Kazuyuki Hida; Shinichiro Ando; Hiroaki Akai; Yasushi Takahashi; Daisuke Koya; Munehiro Kitada; Hisashi Sugano; Tomokazu Nunoue; Akihiko Nakamura; Motofumi Sasaki; Tatsuaki Nakatou; Kei Fujimoto; Daiji Kawanami; Takashi Wada; Nobuyuki Miyatake; Michihiro Yoshida; Kenichi Shikata
Diabetes, obesity & metabolism, Aug. 2022, 24(8):1429 - 1438

A simplified prediction model for end-stage kidney disease in patients with diabetes.
Toyoshi Inoguchi; Tasuku Okui; Chinatsu Nojiri; Erina Eto; Nao Hasuzawa; Yukihiro Inoguchi; Kentaro Ochi; Yuichi Takashi; Fujiyo Hiyama; Daisuke Nishida; Fumio Umeda; Teruaki Yamauchi; Daiji Kawanami; Kunihisa Kobayashi; Masatoshi Nomura; Naoki Nakashima
Scientific reports, 21 Jul. 2022, 12(1):12482 - 12482

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.
Yuki Tanaka; Chikayo Iwaya; Takako Kawanami; Yuriko Hamaguchi; Tsuyoshi Horikawa; Toru Shigeoka; Toshihiko Yanase; Daiji Kawanami; Takashi Nomiyama
Diabetology international, Jul. 2022, 13(3):480 - 492

ROCK2-induced metabolic rewiring in diabetic podocytopathy.
Keiichiro Matoba; Yusuke Takeda; Yosuke Nagai; Kensuke Sekiguchi; Rikako Ukichi; Hiroshi Takahashi; Daisuke Aizawa; Masahiro Ikegami; Toshiaki Tachibana; Daiji Kawanami; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya; Rimei Nishimura
Communications biology, 08 Apr. 2022, 5(1):341 - 341

The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders.
Yuichi Takashi; Daiji Kawanami
International journal of molecular sciences, 21 Feb. 2022, 23(4)

The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) - Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes.
Moritsugu Kimura; Masao Toyoda; Nobumichi Saito; Makiko Takahashi; Konomi Isozumi; Eri Kato; Daiji Kawanami; Masafumi Fukagawa
Diabetes, metabolic syndrome and obesity : targets and therapy, 2022, 15:1627 - 1638

Fibroblast growth factor 23 and kidney function in patients with type 1 diabetes.
Yuichi Takashi; Yasutaka Maeda; Kyoko Toyokawa; Naoki Oda; Rie Yoshioka; Dan Sekiguchi; Masae Minami; Daiji Kawanami
PloS one, 2022, 17(9):e0274182

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Yuichi Takashi; Kyoko Toyokawa; Naoki Oda; Yoshimi Muta; Hisashi Yokomizo; Seiji Fukumoto; Daiji Kawanami
Frontiers in endocrinology, 2022, 13:1004624 - 1004624

Eating before bed and new-onset hypertension in a Japanese population: the Iki city epidemiological study of atherosclerosis and chronic kidney disease.
Shunsuke Funakoshi; Atsushi Satoh; Toshiki Maeda; Miki Kawazoe; Shintaro Ishida; Chikara Yoshimura; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Hitoshi Nakashima; Shigeaki Mukoubara; Hideyuki Fujii; Shota Okutsu; Daiji Kawanami; Shigeki Nabeshima; Seiji Kondo; Masaki Fujita; Kosuke Masutani; Hisatomi Arima
Hypertension research : official journal of the Japanese Society of Hypertension, Dec. 2021, 44(12):1662 - 1667

FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Yuichi Takashi; Daiji Kawanami; Seiji Fukumoto
Current osteoporosis reports, Dec. 2021, 19(6):669 - 675

Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study.
Miki Kawazoe; Shunsuke Funakoshi; Shintaro Ishida; Chikara Yoshimura; Atsushi Satoh; Toshiki Maeda; Masayoshi Tsuji; Soichiro Yokota; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Hideyuki Fujii; Shota Okutsu; Shigeaki Mukobara; Daiji Kawanami; Shigeki Nabeshima; Seiji Kondo; Kosuke Masutani; Hisatomi Arima
Journal of clinical hypertension (Greenwich, Conn.), Dec. 2021, 23(12):2071 - 2077

Comparison of Body Mass Index and Waist Circumference in the Prediction of Diabetes: A Retrospective Longitudinal Study.
Makiko Abe; Hideyuki Fujii; Shunsuke Funakoshi; Atsushi Satoh; Miki Kawazoe; Toshiki Maeda; Kazuhiro Tada; Soichiro Yokota; Toshitaka Yamanokuchi; Chikara Yoshimura; Ryosuke Mimata; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Takeshi Kuga; Shigeki Mukoubara; Kozaburo Akiyoshi; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima
Diabetes therapy : research, treatment and education of diabetes and related disorders, Oct. 2021, 12(10):2663 - 2676

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro.
Leona Yamamoto; Shinichi Yamashita; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Toru Shigeoka; Tsuyoshi Horikawa; Yuki Tanaka; Toshihiko Yanase; Daiji Kawanami; Akinori Iwasaki
Diabetology international, Oct. 2021, 12(4):389 - 398

Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span.
Yuichi Takashi; Shun Sawatsubashi; Itsuro Endo; Yukiyo Ohnishi; Masahiro Abe; Munehide Matsuhisa; Daiji Kawanami; Toshio Matsumoto; Seiji Fukumoto
Biochemistry and biophysics reports, Sep. 2021, 27:101107 - 101107

Effects of Weight Gain after 20 Years of Age and Incidence of Hyper-Low-Density Lipoprotein Cholesterolemia: The Iki Epidemiological Study of Atherosclerosis and Chronic Kidney Disease (ISSA-CKD).
Shota Okutsu; Yoshifumi Kato; Shunsuke Funakoshi; Toshiki Maeda; Chikara Yoshimura; Miki Kawazoe; Atsushi Satoh; Soichiro Yokota; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Hideyuki Fujii; Shigeaki Mukoubara; Hitoshi Nakashima; Daiji Kawanami; Kosuke Masutani; Hisatomi Arima; Shigeki Nabeshima
Journal of clinical medicine, 14 Jul. 2021, 10(14)

Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism.
Midori Minezaki; Yuichi Takashi; Kentaro Ochi; Ryo Mitsuoka; Yuka Yamao; Tadachika Kudo; Daiji Kawanami; Kunihisa Kobayashi; Ichiro Abe
Journal of bone and mineral metabolism, Jul. 2021, 39(4):583 - 588

Eating Speed and Incidence of Diabetes in a Japanese General Population: ISSA-CKD.
Hideyuki Fujii; Shunsuke Funakoshi; Toshiki Maeda; Atsushi Satoh; Miki Kawazoe; Shintaro Ishida; Chikara Yoshimura; Soichiro Yokota; Kazuhiro Tada; Koji Takahashi; Kenji Ito; Tetsuhiko Yasuno; Shota Okutsu; Shigeaki Mukoubara; Hitoshi Nakashima; Shigeki Nabeshima; Seiji Kondo; Masaki Fujita; Kosuke Masutani; Hisatomi Arima; Daiji Kawanami
Journal of clinical medicine, 01 May 2021, 10(9)

Renoprotective Effects of DPP-4 Inhibitors.
Daiji Kawanami; Yuichi Takashi; Hiroyuki Takahashi; Ryoko Motonaga; Makito Tanabe
Antioxidants (Basel, Switzerland), 05 Feb. 2021, 10(2)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Daiji Kawanami; Yuichi Takashi; Yoshimi Muta; Naoki Oda; Dai Nagata; Hiroyuki Takahashi; Makito Tanabe
Frontiers in pharmacology, 2021, 12:754239 - 754239

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet.
Tsuyoshi Horikawa; Takako Kawanami; Yuriko Hamaguchi; Yuki Tanaka; Shotaro Kita; Ryutaro Ryorin; Yuichi Takashi; Hiroyuki Takahashi; Makito Tanabe; Toshihiko Yanase; Daiji Kawanami; Takashi Nomiyama
Heliyon, Nov. 2020, 6(11):e05431

Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Toru Shigeoka; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Tsuyoshi Horikawa; Tomoko Tanaka; Shinichiro Irie; Ryoko Motonaga; Nobuya Hamanoue; Makito Tanabe; Kazuki Nabeshima; Masatoshi Tanaka; Toshihiko Yanase; Daiji Kawanami
Journal of diabetes investigation, Sep. 2020, 11(5):1137 - 1149

ROCK Inhibition May Stop Diabetic Kidney Disease.
Keiichiro Matoba; Yusuke Takeda; Yosuke Nagai; Yasushi Kanazawa; Daiji Kawanami; Tamotsu Yokota; Kazunori Utsunomiya; Rimei Nishimura
JMA journal, 15 Jul. 2020, 3(3):154 - 163

Medical nutrition therapy and dietary counseling for patients with diabetes-energy, carbohydrates, protein intake and dietary counseling.
Toshimasa Yamauchi; Hideki Kamiya; Kazunori Utsunomiya; Hirotaka Watada; Daiji Kawanami; Junko Sato; Munehiro Kitada; Daisuke Koya; Norio Harada; Kenichiro Shide; Erina Joo; Ryo Suzuki; Ryotaro Bouchi; Yasuharu Ohta; Tatsuya Kondo
Diabetology international, Jul. 2020, 11(3):224 - 239

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Yuichi Terawaki; Chikayo Iwaya; Takashi Nomiyama; Dai Shimono; Tsuyoshi Horikawa; Yuki Fujimura-Tanaka; Toru Shigeoka; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase; Daiji Kawanami
Diabetology international, Jul. 2020, 11(3):274 - 282

Significance of Metformin Use in Diabetic Kidney Disease.
Daiji Kawanami; Yuichi Takashi; Makito Tanabe
International journal of molecular sciences, 14 Jun. 2020, 21(12)

Glycolaldehyde induces sensory neuron death through activation of the c-Jun N-terminal kinase and p-38 MAP kinase pathways.
Tomoyo Akamine; Shizuka Takaku; Mari Suzuki; Naoko Niimi; Hideji Yako; Keiichiro Matoba; Daiji Kawanami; Kazunori Utsunomiya; Rimei Nishimura; Kazunori Sango
Histochemistry and cell biology, Feb. 2020, 153(2):111 - 119

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu; Takashi Nomiyama; Tomohiro Numata; Takako Kawanami; Yuriko Hamaguchi; Chikayo Iwaya; Tsuyoshi Horikawa; Yuki Fujimura-Tanaka; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Ryuji Inoue; Toshihiko Yanase; Daiji Kawanami
Endocrine journal, 28 Jan. 2020, 67(1):99 - 106

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms.
Daiji Kawanami; Yuichi Takashi
Frontiers in pharmacology, 2020, 11:967 - 967

ROCK2 regulates TGF-β-induced expression of CTGF and profibrotic genes via NF-κB and cytoskeleton dynamics in mesangial cells.
Yosuke Nagai; Keiichiro Matoba; Daiji Kawanami; Yusuke Takeda; Tomoyo Akamine; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya; Rimei Nishimura
American journal of physiology. Renal physiology, 01 Oct. 2019, 317(4):F839-F851

Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease.
Keiichiro Matoba; Yusuke Takeda; Yosuke Nagai; Daiji Kawanami; Kazunori Utsunomiya; Rimei Nishimura
International journal of molecular sciences, 10 Jul. 2019, 20(14)

ROCK2 Regulates Monocyte Migration and Cell to Cell Adhesion in Vascular Endothelial Cells.
Yusuke Takeda; Keiichiro Matoba; Daiji Kawanami; Yosuke Nagai; Tomoyo Akamine; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya
International journal of molecular sciences, 16 Mar. 2019, 20(6)

Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus.
Akio Nakashima; Keitaro Yokoyama; Daiji Kawanami; Ichiro Ohkido; Mitsuyoshi Urashima; Kazunori Utsunomiya; Takashi Yokoo
Scientific reports, 18 Sep. 2018, 8(1):13999 - 13999

Establishment of a myelinating co-culture system with a motor neuron-like cell line NSC-34 and an adult rat Schwann cell line IFRS1.
Shizuka Takaku; Hideji Yako; Naoko Niimi; Tomoyo Akamine; Daiji Kawanami; Kazunori Utsunomiya; Kazunori Sango
Histochemistry and cell biology, May 2018, 149(5):537 - 543

Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy.
Keiichiro Matoba; Daiji Kawanami; Yosuke Nagai; Yusuke Takeda; Tomoyo Akamine; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya
International journal of molecular sciences, 18 Aug. 2017, 18(8)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Daiji Kawanami; Keiichiro Matoba; Yusuke Takeda; Yosuke Nagai; Tomoyo Akamine; Tamotsu Yokota; Kazunori Sango; Kazunori Utsunomiya
International journal of molecular sciences, 18 May 2017, 18(5)

Signaling pathways in diabetic nephropathy.
Daiji Kawanami; Keiichiro Matoba; Kazunori Utsunomiya
Histology and histopathology, Oct. 2016, 31(10):1059 - 67

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
Daiji Kawanami; Keiichiro Matoba; Kazunori Sango; Kazunori Utsunomiya
International journal of molecular sciences, 29 Jul. 2016, 17(8)

Detection of hemoglobin variant HbS on the basis of discrepant HbA1c values in different measurement methods.
Yusuke Takeda; Daiji Kawanami; Kazunori Utsunomiya
Diabetology international, Jun. 2016, 7(2):199 - 203

[Epidemiology of diabetic nephropathy].
Daiji Kawanami; Kazunori Utsunomiya
Nihon rinsho. Japanese journal of clinical medicine, Apr. 2016, 74 Suppl 2:153 - 7

[Transition and perspectives of antidiabetic agents].
Daiji Kawanami; Kazunori Utsunomiya
Nihon rinsho. Japanese journal of clinical medicine, Mar. 2015, 73(3):375 - 81

Sphingosine-1-phosphate induces differentiation of cultured renal tubular epithelial cells under Rho kinase activation via the S1P2 receptor.
Sho Ishizawa; Junko Takahashi-Fujigasaki; Yasushi Kanazawa; Keiichiro Matoba; Daiji Kawanami; Tamotsu Yokota; Takeo Iwamoto; Naoko Tajima; Yoshinobu Manome; Kazunori Utsunomiya
Clinical and experimental nephrology, Dec. 2014, 18(6):844 - 52

Rho-kinase regulation of TNF-α-induced nuclear translocation of NF-κB RelA/p65 and M-CSF expression via p38 MAPK in mesangial cells.
Keiichiro Matoba; Daiji Kawanami; Masami Tsukamoto; Jun Kinoshita; Tomoko Ito; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Noriyuki Murai; Senya Matsufuji; Kazunori Utsunomiya
American journal of physiology. Renal physiology, 01 Sep. 2014, 307(5):F571-80

The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells.
Yasushi Kanazawa; Junko Takahashi-Fujigasaki; Sho Ishizawa; Naoko Takabayashi; Kumiko Ishibashi; Keiichiro Matoba; Daiji Kawanami; Tamotsu Yokota; Naoko Tajima; Kazunori Utsunomiya
Experimental neurology, Sep. 2013, 247:438 - 46

Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Keiichiro Matoba; Daiji Kawanami; Rina Okada; Masami Tsukamoto; Jun Kinoshita; Tomoko Ito; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Noriyuki Murai; Senya Matsufuji; Junko Takahashi-Fujigasaki; Kazunori Utsunomiya
Kidney international, Sep. 2013, 84(3):545 - 54

Fasudil inhibits ER stress-induced VCAM-1 expression by modulating unfolded protein response in endothelial cells.
Daiji Kawanami; Keiichiro Matoba; Rina Okada; Masami Tsukamoto; Jun Kinoshita; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya
Biochemical and biophysical research communications, 31 May 2013, 435(2):171 - 5

Successful control of a case of severe insulin allergy with liraglutide.
Daiji Kawanami; Tomoko Ito; Yui Watanabe; Jun Kinoshita; Masaya Sakamoto; Tsuyoshi Isaka; Kazunori Utsunomiya
Journal of diabetes investigation, 29 Jan. 2013, 4(1):94 - 6

Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation.
Saptarsi M Haldar; Darwin Jeyaraj; Priti Anand; Han Zhu; Yuan Lu; Domenick A Prosdocimo; Betty Eapen; Daiji Kawanami; Mitsuharu Okutsu; Leticia Brotto; Hisashi Fujioka; Janos Kerner; Mariana G Rosca; Owen P McGuinness; Rod J Snow; Aaron P Russell; Anthony N Gerber; Xiaodong Bai; Zhen Yan; Thomas M Nosek; Marco Brotto; Charles L Hoppel; Mukesh K Jain
Proceedings of the National Academy of Sciences of the United States of America, 24 Apr. 2012, 109(17):6739 - 44

Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells.
Daiji Kawanami; Keiichiro Matoba; Yasushi Kanazawa; Sho Ishizawa; Tamotsu Yokota; Kazunori Utsunomiya
Biochemical and biophysical research communications, 12 Aug. 2011, 411(4):798 - 803

The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock.
Ganapati H Mahabeleshwar; Daiji Kawanami; Nikunj Sharma; Yoichi Takami; Guangjin Zhou; Hong Shi; Lalitha Nayak; Darwin Jeyaraj; Robert Grealy; Mary White; Ross McManus; Thomas Ryan; Patrick Leahy; Zhiyong Lin; Saptarsi M Haldar; G Brandon Atkins; Hector R Wong; Jerry B Lingrel; Mukesh K Jain
Immunity, 27 May 2011, 34(5):715 - 28

Rho-kinase mediates TNF-α-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells.
Keiichiro Matoba; Daiji Kawanami; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya
Biochemical and biophysical research communications, 26 Nov. 2010, 402(4):725 - 30

Kruppel-like factor 2 regulates endothelial barrier function.
Zhiyong Lin; Viswanath Natesan; Hong Shi; Fei Dong; Daiji Kawanami; Ganapati H Mahabeleshwar; G Brandon Atkins; Lalitha Nayak; Yingjie Cui; James H Finigan; Mukesh K Jain
Arteriosclerosis, thrombosis, and vascular biology, Oct. 2010, 30(10):1952 - 9

A novel role of CCN3 in regulating endothelial inflammation.
Zhiyong Lin; Viswanath Natesan; Hong Shi; Anne Hamik; Daiji Kawanami; Caili Hao; Ganapati H Mahabaleshwar; Weiye Wang; Zheng-Gen Jin; G Brandon Atkins; Sue M Firth; Laure Rittié; Bernard Perbal; Mukesh K Jain
Journal of cell communication and signaling, Oct. 2010, 4(3):141 - 53

[The clinical significance of early intervention for impaired glucose tolerance].
Daiji Kawanami; Kazunori Utsunomiya
Nihon rinsho. Japanese journal of clinical medicine, May 2010, 68(5):797 - 802

Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation.
Saptarsi M Haldar; Yuan Lu; Darwin Jeyaraj; Daiji Kawanami; Yingjie Cui; Sam J Eapen; Caili Hao; Yan Li; Yong-Qiu Doughman; Michiko Watanabe; Koichi Shimizu; Helena Kuivaniemi; Junichi Sadoshima; Kenneth B Margulies; Thomas P Cappola; Mukesh K Jain
Science translational medicine, 07 Apr. 2010, 2(26):26ra26

Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium.
Daiji Kawanami; Ganapati H Mahabeleshwar; Zhiyong Lin; G Brandon Atkins; Anne Hamik; Saptarsi M Haldar; Koji Maemura; Joseph C Lamanna; Mukesh K Jain
The Journal of biological chemistry, 31 Jul. 2009, 284(31):20522 - 30

Hemizygous deficiency of Krüppel-like factor 2 augments experimental atherosclerosis.
G Brandon Atkins; Yunmei Wang; Ganapati H Mahabeleshwar; Hong Shi; Huiyun Gao; Daiji Kawanami; Viswanath Natesan; Zhiyong Lin; Daniel I Simon; Mukesh K Jain
Circulation research, 26 Sep. 2008, 103(7):690 - 3

C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells.
Daiji Kawanami; Koji Maemura; Norihiko Takeda; Tomohiro Harada; Takefumi Nojiri; Tetsuya Saito; Ichiro Manabe; Yasushi Imai; Ryozo Nagai
Atherosclerosis, Mar. 2006, 185(1):39 - 46

Genetic analysis in a patient with recurrent cardiac myxoma and endocrinopathy.
Yasushi Imai; Tsuyoshi Taketani; Koji Maemura; Norihiko Takeda; Tomohiro Harada; Takefumi Nojiri; Daiji Kawanami; Koshiro Monzen; Dobun Hayashi; Yuji Murakawa; Minoru Ohno; Yoshinobu Hirata; Tsutomu Yamazaki; Shinichi Takamoto; Ryozo Nagai
Circulation journal : official journal of the Japanese Circulation Society, Aug. 2005, 69(8):994 - 5

Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1.
Norihiko Takeda; Koji Maemura; Yasushi Imai; Tomohiro Harada; Daiji Kawanami; Takefumi Nojiri; Ichiro Manabe; Ryozo Nagai
Circulation research, 23 Jul. 2004, 95(2):146 - 53

Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions.
Daiji Kawanami; Koji Maemura; Norihiko Takeda; Tomohiro Harada; Takefumi Nojiri; Yasushi Imai; Ichiro Manabe; Kazunori Utsunomiya; Ryozo Nagai
Biochemical and biophysical research communications, 06 Feb. 2004, 314(2):415 - 9

A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population.
Tomohiro Harada; Yasushi Imai; Takefumi Nojiri; Hiroyuki Morita; Doubun Hayashi; Koji Maemura; Keiko Fukino; Daiji Kawanami; Go Nishimura; Kensuke Tsushima; Koshiro Monzen; Tadashi Yamazaki; Satoshi Mitsuyama; Takahiko Shintani; Narimasa Watanabe; Kumiko Seto; Takao Sugiyama; Fumitaka Nakamura; Minoru Ohno; Yasunobu Hirata; Tsutomu Yamazaki; Ryozo Nagai
Atherosclerosis, Jul. 2003, 169(1):105 - 12

フレイル・サルコペニアを考慮した高齢者糖尿病
山本真悠子; 川浪大治
臨牀と研究, May 2026, 103(5):110 - 116

合併症・併存症の食事療法
山本真悠子、川浪大治
専門研修マスターノート 糖尿病, May 2026, :292 - 295

ROCK研究の最前線 ー大血管症ー
大橋慎史; 川浪大治
糖尿病, May 2026, 69(4):128 - 130

生活習慣と脂質異常症
川浪大治
臨牀と研究, Feb. 2026, 103(2):42 - 45

代謝 Q99-101
川浪大治
THE 総合内科ドリル(Ver.2)1, Jul. 2025, :219 - 224

糖尿病治療薬以外で低血糖に注意が必要なものはある？
山本真悠子; 川浪大治
糖尿病ケア, Jul. 2025, 22(4):92 - 93

糖尿病治療薬で低血糖に注意が必要なものはある？
山本真悠子; 川浪大治
糖尿病ケア, Jul. 2025, 22(4):90 - 91

糖尿病性腎症関連治療薬の眼合併症に対する影響
川浪大治
糖尿病合併症, Jun. 2025, 39(1):30 - 33

血管内皮機能制御因子と糖尿病性腎症進展機構への関与
川浪大治
糖尿病合併症, Jun. 2025, 34(2):195 - 198

GLP-1受容体作動薬（肥満症を含めて）
横溝 久; 川浪大治
糖尿病, May 2025, 68(5):143 - 147

糖尿病性腎症の治療
川浪大治
日本内科学会雑誌, Apr. 2025, 114:656 - 663

Ⅱ. 食事療法 4. 糖尿病性腎症合併時
川浪大治
糖尿病最新の治療 2025-2027, Apr. 2025, :97 - 99

臨床データからみるGIP/GLP-1受容体作動薬の多面的作用② 体重減少作用
牟田芳美; 川浪大治
薬局, Apr. 2025, 76(5):31 - 34

糖尿病関連腎臓病の薬物療法の進歩
川浪大治
糖尿病・内分泌プラクティス, Mar. 2025, 3(2):0020

腎症の診断、評価のための検査
横溝 久; 川浪大治
日本臨床増刊号 新時代の臨床糖尿病学, Feb. 2025, 83(2):282 - 288

糖尿病における脂質代謝異常
山本真悠子; 川浪大治
臨床と研究, Jan. 2025, 102(1):31 - 35

糖尿病性ケトアシドーシス
川浪大治
今日の治療指針, Jan. 2025, :738 - 739

慢性腎臓病合併2型糖尿病におけるGLP-1受容体作動薬の腎アウトカム：日本からの展望
川浪大治
新薬と臨床, Aug. 2024, 73(8):736 - 758

糖尿病患者の救急医療・急性期医療 5 乳酸アシドーシス
牟田芳実; 川浪大治
月刊糖尿病, Jul. 2024, 16(1):33 - 38

内科医からみた糖尿病網膜症
川浪大治
日本糖尿病合併症, Jun. 2024, 38(1):42 - 45

糖尿病性腎症における新規MR拮抗薬への期待と課題
川浪大治
糖尿病学2024, May 2024, :120 - 127

Q. 血圧はいつも130 mmHg程度ですよ. それなのに血圧の薬を飲まないとだめですか？
山本真悠子、川浪大治
臨床雑誌「内科」特集 患者さんからよく尋ねられる内科診療のQuestion, Apr. 2024, 133(4):982 - 984

スルホニル尿素薬とイメグリミンから考えるインスリン分泌促進薬
川浪大治
臨床と研究, Feb. 2024, 101(2):20 - 23

糖尿病性腎症に関する現状と今後の展望
横溝 久; 川浪大治
日本体質医学会誌, 2024, 86(2):87 - 95

糖尿病性腎臓病の課題と展望
川浪大治
臨床と研究, Aug. 2023, 100(8):1027 - 1032

糖尿病食事療法の考え方
川浪大治
食と医療, Aug. 2023, 26:76 - 78

イメグリミンへの期待
川浪大治
月刊保団連, Jul. 2023, 1399:40 - 43

糖尿病性腎臓病の成因としての骨腎連関とRho-kinaseの関与
川浪大治
糖尿病合併症, Jul. 2023, 37(2):236 - 240

糖尿病性腎臓病の治療の進歩
川浪大治
月刊 糖尿病, Jun. 2023, 15(4):69 - 75

メトホルミン再考
川浪大治
月刊保団連, Jun. 2023, 1398:36 - 39

GIP/GLP-1受容体作動薬チルゼパチドの登場
川浪大治
月刊保団連, May 2023, 1397:36 - 40

糖尿病性腎臓病の治療の進歩
川浪大治
月刊保団連, Apr. 2023, 1396:40 - 43

特集 -自信がもてるようになる!-エビデンスに基づく｢糖尿病診療｣大全-新薬からトピックスまで 【Ⅰ章】｢薬物療法｣の新スタンダード ❷糖尿病に合併した｢高血圧症｣｢脂質異常症｣の薬剤選択
横溝 久; 川浪 大治
総合診療, 15 Mar. 2023, 33(3):268 - 272

糖尿病性腎臓病の成因
川浪大治
月刊保団連, Mar. 2023, 1394:42 - 45

糖尿病食事療法の考え方
川浪大治
月刊保団連, Feb. 2023, 1389:43 - 46

メディカルスタッフの現状と課題：糖尿病チーム医療，資格取得，学会発表，臨床研究，論文投稿，ジェンダー
Sato Asako; Kawanami Daiji; Fujikawa Rumi; Suganuma Yumi; Furuhashi Masato; Morino Katsutaro; Yamamoto Kyoko; Wada Mikiko; Imachi Hitomi; Okada Yukiko; Kawasaki Maki; Kondo Keiichi; Sasaoka Toshiyasu; Takahashi Noriko; Togashi Yu; Nakajima Hanako; Hashimoto Naoko; Fujimoto Kei; Bessho Ryoichi; Matoba Yuka; Miya Aika; Abiko Atsuko
Journal of the Japan Diabetes Society, 30 Jan. 2023, 66(1):118 - 128

糖尿病性腎症病期分類 2023 の策定
馬場園 哲也, 金崎 啓造, 宇都宮 一典, 古家 大祐, 綿田 裕孝, 繪本 正憲, 川浪 大治, 深水 圭, 久米 真司, 鈴木 芳樹, 和田 淳, 和田 隆志, 岡田 浩一, 成田 一衛, 小岩 文彦, 阿部 雅紀, 土谷 健, 加藤 明彦, 市川 和子, 北谷 直美
日本腎臓学会誌, 2023, 65(7):847 - 856

糖尿病性腎症病期分類2023の策定
馬場園 哲也, 金崎 啓造, 宇都宮 一典, 古家 大祐, 綿田 裕孝, 繪本 正憲, 川浪 大治, 深水 圭, 久米 真司, 鈴木 芳樹, 和田 淳, 和田 隆志, 岡田 浩一, 成田 一衛, 小岩 文彦, 阿部 雅紀, 土谷 健, 加藤 明彦, 市川 和子, 北谷 直美
日本透析医学会誌, 2023, 56(11):393 - 400

糖尿病性腎症病期分類2023の策定
馬場園 哲也; 金崎 啓造; 宇都宮 一典; 古家 大祐; 綿田 裕孝; 繪本 正憲; 川浪 大治; 深水 圭; 久米 真司; 鈴木 芳樹; 和田 淳; 和田 隆志; 岡田 浩一; 成田 一衛; 小岩 文彦; 阿部 雅紀; 土谷 健; 加藤 明彦; 市川 和子; 北谷 直美
糖尿病, 2023, 66(11):797 - 805

皮膚科医に知って欲しい、患者をその気にさせる理想的な減量法
川浪大治
Visual Dermatology, May 2022, 21(6):602 - 605

糖尿病性腎症・糖尿病性腎臓病
小田直樹; 川浪大治
臨床雑誌 内科, Apr. 2022, 129(4):1013 - 1018

糖尿病腎症「見える化」
川浪大治; 宇都宮一典
糖尿病のハテナがわかる！イラストBOOK, Jan. 2022, :42 - 43

SGLT2阻害薬
川浪大治
糖尿病最新の治療 2022-2024, Nov. 2021, :124 - 127

【内分泌疾患・糖尿病・代謝疾患-診療のエッセンス】(II章)糖尿病 食事療法
川浪 大治
日本医師会雑誌, Oct. 2021, 150(特別2):S171 - S174

糖尿病性腎症における食事療法の考え方
川浪大治
日本医事新報, Apr. 2021, 5058:44

脂質異常症
川浪大治
糖尿病性腎臓病の病態と治療, Apr. 2021, :115 - 118

症例から考える合併症管理の戦略 糖尿病性腎症の症例
川浪大治
徹底解説！糖尿病合併症管理・フォローアップ, Feb. 2021, :152 - 154

高浸透圧、高血糖状態、乳酸アシドーシス
川浪大治
今日の治療指針2021, Jan. 2021, :772 - 773

糖尿病合併症の成因と治療―心腎連関の観点から―
川浪大治
診断と治療, May 2020, 97(5):124 - 128

アルコール飲料の摂取と糖尿病の管理
月刊 糖尿病, Nov. 2019, 11(5):68 - 73

腎不全
森武美帆; 川浪大治
診断と治療, Sep. 2019, 107(9):1075 - 1081

【この薬,一生続けるんですか?】糖尿病・内分泌系薬剤 インスリン
森武 美帆; 川浪 大治
内科, Mar. 2019, 123(3):399 - 401

包括的リハビリテーション医療の構成要素としての栄養療法 リハビリテーション科医が知っておくべき基本知識 糖尿病と食事療法
川浪 大治; 宇都宮 一典
Journal of Clinical Rehabilitation, Mar. 2019, 28(3):283 - 287

座談会 高齢者糖尿病の治療戦略UPDATE
綿田 裕孝; 鈴木 亮; 川浪 大治; 田村 好史
Diabetes update = ダイアベーテスアップデート : frontiers in diabetes, Feb. 2019, 8(1):4 - 13

【糖尿病と栄養】 日本における糖尿病の食事療法 その現状と課題
川浪 大治; 宇都宮 一典
栄養, Jun. 2018, 3(2):81 - 87

【SGLT2阻害薬の最新のエビデンスと予期せぬ功罪】 CANVAS試験
川浪 大治; 宇都宮 一典
内分泌・糖尿病・代謝内科, Apr. 2018, 46(4):225 - 231

【腎と糖尿病:変革期の診断と治療】 【DKD変革期の診断】腎症病期分類
川浪 大治; 宇都宮 一典
腎と透析, Feb. 2018, 84(2):196 - 201

【エビデンスを2型糖尿病臨床にどう生かせばいい?-Evidence Based MedicineをReal Worldへ】糖尿病薬物療法 SGLT2阻害薬
川浪 大治
内科, Jan. 2018, 121(1):81 - 83

【糖尿病介入研究と動脈硬化】 LEADER Liraglutide(GLP-1受容体作動薬)追加使用の長期心血管転帰
川浪 大治; 宇都宮 一典
動脈硬化予防, Dec. 2017, 16(4):18 - 25

【高齢者糖尿病-病態・臨床の最新知見-】高齢者糖尿病の管理・治療上の留意点 食事療法
大村 有加; 川浪 大治; 宇都宮 一典
日本臨床, Nov. 2017, 75(11):1671 - 1677

【診断と治療のABC[124]糖尿病合併症】 (第5章)合併症治療のエビデンスと今後の展望 生活習慣の修正 食事療法
川浪 大治; 宇都宮 一典
最新医学 別冊(糖尿病合併症), Jul. 2017, :234 - 241

【開かれた透析医療-Integrated Careの具現化】 糖尿病透析患者の包括的ケア
川浪 大治; 宇都宮 一典
臨床透析, Jan. 2017, 33(1):61 - 67

【経口糖尿病治療薬2016-病態に応じたベストチョイス】 SGLT2阻害薬,食後高血糖改善薬 食後高血糖改善薬の服薬アドヒアランスを高める
川浪 大治; 森 豊
糖尿病診療マスター, Nov. 2016, 14(11):884 - 887

【Combination therapyによる最新糖尿病治療戦略】 海外のガイドラインから見たinitial combination therapyのあり方
川浪 大治
糖尿病の最新治療, Nov. 2016, 8(1):8 - 12

【糖尿病治療における食事療法の課題と展望-新たなエビデンスに基づいた食事療法】 アルコール
川浪 大治; 宇都宮 一典
カレントテラピー, Jun. 2016, 34(6):554 - 558

【糖尿病と腎泌尿器疾患】 糖尿病性腎症の細胞内情報伝達系
川浪 大治; 宇都宮 一典
腎臓内科・泌尿器科, Jun. 2016, 3(6):557 - 564

【新時代の臨床糖尿病学(下)-より良い血糖管理をめざして-】 糖尿病合併症 発症・進展の分子機序 Rho/Rho-kinase
川浪 大治; 宇都宮 一典
日本臨床, Apr. 2016, 74(増刊2 新時代の臨床糖尿病学(下)):77 - 83

【新時代の臨床糖尿病学(下)-より良い血糖管理をめざして-】 糖尿病合併症の病態・診断・治療 慢性合併症 糖尿病腎症 糖尿病腎症の疫学
川浪 大治; 宇都宮 一典
日本臨床, Apr. 2016, 74(増刊2 新時代の臨床糖尿病学(下)):153 - 157

【患者さんがみるみる変わる!ダウンロードでそのまま使える!魔法の糖尿病患者説明シート50+α】 (第2章)糖尿病のリスク・合併症の患者説明シート16 糖尿病腎症見える化シート
川浪 大治; 宇都宮 一典
糖尿病ケア, Mar. 2016, 74(2016春季増刊) - 78

【あなたも名医!糖尿病性腎症をどう治療する?外来でここまでやろう!】 (1章)糖尿病性腎症の基本を押さえておこう! 糖尿病性腎症の診断と問題点
川浪 大治; 宇都宮 一典
jmed mook, Feb. 2016, (42):29 - 31

【糖尿病治療薬Update-適正使用に向けて】 2型糖尿病治療 第一選択薬と併用療法 initial combination治療は是か非か?
川浪 大治; 森 豊
Medicina, Jan. 2016, 53(1):62 - 64

【SGLT2阻害薬の新時代〜機序から臨床まで】 SGLT2阻害薬の適正使用と注意点について
川浪 大治; 宇都宮 一典
月刊糖尿病, Jul. 2015, 7(7):54 - 58

SGLT・レッスン SGLT2阻害薬を服用している患者さんの食事療法について
川浪 大治; 宇都宮 一典
Diabetes Update, Jul. 2015, 4(3):142 - 145

【糖尿病と合併症(後篇) 糖尿病合併症】 糖尿病慢性合併症の発症メカニズム ERストレスと腎障害
川浪 大治
最新医学, Jul. 2015, 70(7月増刊):1375 - 1381

【糖尿病治療薬update-適正な血糖管理を目指して-】 糖尿病治療薬の変遷と今後の展望
川浪 大治; 宇都宮 一典
日本臨床, Mar. 2015, 73(3):375 - 381

よく使う日常治療薬の正しい使い方 SGLT2阻害薬の正しい使い方 積極的に、しかし慎重に
川浪 大治; 宇都宮 一典
レジデントノート, Feb. 2015, 16(16):3034 - 3037

【SGLT2阻害薬-摩訶不思議な糖尿病治療薬】治療薬解説 SGLT2阻害薬の薬物治療
高橋 紘; 川浪 大治; 宇都宮 一典
カレントテラピー, Jan. 2015, 33(1):64 - 70

【CKDにおける血管病変の進展】 CKDでの血管病変進展機序 血管病変進展面での糖尿病と非糖尿病CKDの相違
川浪 大治; 宇都宮 一典
血管医学, Oct. 2014, 15(3):275 - 280

【糖尿病・肥満の新規治療薬-SGLT2阻害薬とリパーゼ阻害薬-】 SGLT2阻害薬の基礎と臨床 SGLT2阻害薬の種類とその効果
川浪 大治; 宇都宮 一典
プラクティス, Sep. 2014, 31(5):603 - 611

注目される用語の解説 Rho-kinase
川浪 大治; 宇都宮 一典
動脈硬化予防, Aug. 2014, 13(2):69 - 70

【新たなSGLT2阻害薬に期待される作用とその効果】 SGLT2阻害薬投与後に留意すべき食事療法
川浪 大治; 宇都宮 一典
Progress in Medicine, Apr. 2014, 34(4):697 - 700

腎臓における糖代謝調節機構と治療学的意義
川浪 大治; 宇都宮 一典
内分泌・糖尿病・代謝内科, Jan. 2014, 38(1):103 - 108

【2型糖尿病治療の新時代を迎えて】 Na+/グルコース共役輸送担体(SGLT2)阻害薬 SGLT2阻害薬の構造と血糖低下作用特性
川浪 大治; 宇都宮 一典
Diabetes Frontier, Dec. 2013, 24(6):711 - 716

心血管疾患リスクとその対策 糖尿病合併脂質異常症の危険因子とその対策
川浪 大治; 宇都宮 一典
循環plus, Dec. 2013, 14(3):7 - 9

【SGLT2阻害薬の正体を知る】 SGLT2阻害薬と心血管イベント
川浪 大治; 宇都宮 一典
ホルモンと臨床, Oct. 2013, 61(10):779 - 783

【糖尿病の実地診療 治療の進化を臨床現場で生かす】 治療の進化に基づく着実な実地診療の進めかた 実地医家に不可欠な糖尿病合併症の実地診療
川浪 大治; 宇都宮 一典
Medical Practice, May 2013, 30(5):746 - 753

【糖尿病腎症-透析をいかに防ぐか-】 腎症治療における脂質管理
川浪 大治; 宇都宮 一典
プラクティス, Mar. 2013, 30(2):199 - 205

【糖尿病合併症の成因と治療】 糖尿病腎症 新たな治療戦略
川浪 大治; 宇都宮 一典
Medical Science Digest, Jul. 2012, 38(8):346 - 349

【糖尿病合併症の成因と薬物療法】 合併症の成因を標的とした薬物療法の開発 Rhoキナーゼ阻害薬
川浪 大治; 宇都宮 一典
月刊糖尿病, Jul. 2012, 4(8):109 - 117

【糖尿病腎症-成因、診断、治療法の最近の進歩】 糖尿病腎症の治療 腎症における脂質コントロールの意義と病期別のエビデンス
川浪 大治; 宇都宮 一典
内分泌・糖尿病・代謝内科, Jun. 2012, 34(6):543 - 549

【糖尿病の血管合併症】 糖尿病腎症の新しい病期分類
川浪 大治; 宇都宮 一典
The Lipid, Apr. 2012, 23(2):172 - 178

【糖尿病性腎症治療と腎症治療薬の新しい展望】 糖尿病性腎症の治療 脂質管理
川浪 大治; 宇都宮 一典
Medicinal, Feb. 2012, 2(2):59 - 67

動脈硬化micro¯o 糖尿病と動脈硬化
川浪 大治; 宇都宮 一典
循環plus, Jul. 2011, 11(10):10 - 12

【糖尿病性腎症とCKD-新たな展開と治療法の選択-】 糖尿病性腎症の治療 脂質コントロール その重要性と用いる薬剤の選択
川浪 大治; 宇都宮 一典
月刊糖尿病, Jul. 2011, 3(7):98 - 103

【糖尿病大血管症の最新医療】 大血管症リスクとしての腎症
川浪 大治; 宇都宮 一典
Pharma Medica, Feb. 2011, 29(2):29 - 32

糖尿病・代謝症候群の成因と病態 糖尿病性昏睡
川浪 大治; 宇都宮 一典
医学のあゆみ 別冊(糖尿病・代謝症候群ーstate of arts2004-2006), Jun. 2004, :267 - 269

糖尿病性腎症保護因子PKM2に着目した残存病態の解明と新規治療法の開発
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C)
Fukuoka University
01 Apr. 2024 - 31 Mar. 2027

慢性腎臓病患者の健康寿命の延伸を目指した生体のリン感知機構の解明
日本学術振興会, 科学研究費助成事業, 基盤研究(C)
福岡大学
01 Apr. 2023 - 31 Mar. 2027

糖尿病性腎臓病におけるリン代謝とRho-kinaseの意義
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C)
Fukuoka University
01 Apr. 2022 - 31 Mar. 2025

ペプチド医薬の超長期滞留性DDSの開発
AMED, 橋渡し研究プログラム 異分野融合型研究シーズ（シーズH）
福岡大学病院
2022 - 2023

糸球体内皮機能障害による糖尿病性腎臓病発症・進展機構の解明
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C)
Fukuoka University
01 Apr. 2019 - 31 Mar. 2022

mDia1による血管内皮機能調節機構の解明
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C)
01 Apr. 2016 - 31 Mar. 2020

ＲＯＣＫ２によるポドサイト機能調節機構と糖尿病腎症への関与
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C)
Jikei University School of Medicine
01 Apr. 2015 - 31 Mar. 2019

ＲＯＣＫ２による血管内皮機能調節機構の解明
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Young Scientists (B)
Jikei University School of Medicine
2011 - 2013